Cancer drug hope raises Genmab's spirits after legal defeat

Biotech firm Genmab and partner Abbvie have delivered promising topline data from their shared drug hope epcoritamab, a bone marrow cancer treatment. An important validation for Genmab, assesses an analyst, as the company recently lost an important legal battle.

Photo: Joost Melis / Genmab / PR

The show must go on, as the saying goes, which is also true for the biotech sector.

Although the wind was knocked out of Genmab shortly before Easter when the company’s partner Janssen won a legal case against the firm, things are brightening up.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs